Search

Now showing items 1-8 of 8

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

2019- White, H. D.; Steg, P. G.; Szarek, M.; Bhatt, D. L.; Bittner, V. A.; [et al.]

Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

2019- Steg, P. G.; Szarek, M.; Bhatt, D. L.; Bittner, V. A.; Bregeault, M. F.; [et al.]

Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

2019- Roe, M. T.; Li, Q. H.; Bhatt, D. L.; Bittner, V. A.; Diaz, R.; [et al.]

1-Year COMBO stent outcomes stratified by the PARIS bleeding prediction score: From the MASCOT registry

2020- Chandrasekhar, J.; Baber, U.; Sartori, S.; Aquino, M. B.; Hájek, P.; [et al.]

New Cancer Diagnosis After Bleeding in Anticoagulated Patients With Atrial Fibrillation

2020- Raposeiras Roubín, Sergio; Abuassi ., Emad; Barreiro Pardal, C.; Cespón Fernández, Maria; Muñoz Pousa, Isabel; [et al.]

Major Bleeding Predictors in Patients with Left Atrial Appendage Closure: The Iberian Registry II

2020- Lopez-Minguez, J. R.; Nogales-Asensio, J. M.; De Oliveira, E. I.; Santos, L.; Ruiz-Salmeron, R.; [et al.]

Comparison of long-term clinical outcomes in multivessel coronary artery disease patients treated either with bioresoarbable polymer sirolimus-eluting stent or permanent polymer everolimus-eluting stent: 5-year results of the CENTURY II randomized clinical trial

2020- Iñiguez Romo, Andres; Chevalier, B.; Richardt, G.; Neylon, A.; Jiménez Díaz, Victor Alfonso; [et al.]

Patients' knowledge about their involvement in clinical trials. A non-randomized controlled trial.

2022- Juan Salvadores, Pablo; Sánchez Michel Gómez, Marcela; Jiménez Díaz, Victor Alfonso; Martínez Reglero, Cristina; Iñiguez Romo, Andres